GSK resumes commercial operations in Venezuela

Global pharmaceutical company GlaxoSmithKline (GlaxoSmithKline) was announced on September 7, with pharmaceutical laboratory.

At a news conference at the Laboratorios Farma headquarters in Caracas, the two companies reported the re-entry of four drugs produced at GlaxoSmithKline’s international plant into the Venezuelan market.

drug is Demowatt (topical corticosteroids), Kepra (antiepileptic drugs), Paroxetine (antidepressants) and Centec (Anti-Allergy), which will now be distributed by Laboratorios Farma to the main pharmacies and pharmacy network in the country.

You might be interested in: Consumption of Generic Drugs Growing in Venezuela, A Report Says

“The idea is to gradually roll out the entire product portfolio, including the vaccines, in the medium term as we comply with the regulatory requirements of the Ministry of Health and the Institute of Health,” he said. Alejandro Kanakis

General Manager, Central America, Caribbean and Venezuela, GlaxoSmithKline (GSK). “We’re here for the long-term stay.”

Jose Ignacio de OteizaThe managing director of Laboratorios Farma in Venezuela explained that the alliance was formed to bring quality medicines to the country and it took two years to realize it.

The four drugs are already on the market in Venezuela and they want to maintain a steady supply, the spokesman said.

GSK’s vaccine and other plans in Venezuela

Among the companies’ plans is to resume commercialization of anti-infectives and other epilepsy drugs, as well as asthma and chronic obstructive pulmonary disease drugs, he said. Jerome EspinosaMedical Director, GSK Central America, Caribbean and Venezuela.

There is currently no projected date for the commercialization of the vaccine. However, a spokesperson confirmed they won’t be arriving in 2023.

“We have to start the registration process. It’s not something that’s going to happen in the short term, but we’re already working towards them. It is a combination of more than 15 vaccines worldwide, Rotavirus, hepatitis A and B, chickenpox, diphtheria, tetanus, and pneumococcus. The portfolio is huge and our idea is to be able to launch the entire portfolio again in the country. ’ Kanakis added.

Espinosa said they also hope to join the Society of Medical Sciences at the main congress in the country.

Grupo Farma, a multinational company of Swiss origin, celebrates its 83rd anniversary in Venezuela in 2023.

GSK is a British multinational company with operations in more than 120 countries and 47 pharmaceutical factories around the world. Twenty years ago they had a factory in Venezuela, but it is no longer in operation.

“The plant closure was a search for efficiencies on a global scale. Multinationals sought to concentrate their production in a few very efficient, high-productivity plants and distribute from there,” Kanakis added. “The most important thing is quality and availability, and that’s what we guarantee.”

Although the company ceased commercialization of the product until 2023, it maintained its presence in the country. National manufacturing is not foreseen in its current plans.

related